No single platform wins for everyone. Ro tends to lean toward branded medication and structured clinician contact, Henry Meds built its name on low flat-price compounded programs, and Hims sits in between with a large consumer brand and shifting product mix. The right pick depends on whether you want an FDA-approved branded drug or a compounded one, what the monthly price actually includes, and how much clinical oversight you get for it.
What are these platforms actually selling?
All three are telehealth companies that connect patients with licensed clinicians who can prescribe GLP-1 medication for weight management. That shared description hides the real difference. Some months a platform routes patients toward branded semaglutide or tirzepatide, other months toward a compounding pharmacy, and the mix shifts with supply and state rules.
Ro, reachable at ro.co, has generally positioned itself around branded access and connecting patients to insurance and manufacturer programs when possible. Henry Meds made its reputation on flat monthly cash pricing for compounded medication, aimed squarely at people whose plans exclude weight drugs. Hims runs a large direct-to-consumer brand across many conditions, with a GLP-1 offering that has included both compounded and branded routes over time. The label on the app tells you less than the medication class in the box.
Branded or compounded: why does it decide everything?
This is the fork that matters. Branded semaglutide and tirzepatide are FDA-approved and backed by the trial record. Tirzepatide’s obesity data comes from the SURMOUNT program, including the 72-week SURMOUNT-1 trial and follow-up work such as SURMOUNT-4 on maintaining weight reduction and SURMOUNT-CN in Chinese adults. A 2024 head-to-head comparison of semaglutide and tirzepatide for weight loss gave clinicians direct evidence rather than cross-trial guesswork.
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule, but they have not been through the approval process that generated that evidence. A 2025 pharmacovigilance study of compounded GLP-1 products in the FDA adverse event reporting system, and a documented poison control case series on administration errors with compounded semaglutide, both point to a real safety gap tied to dosing and handling rather than the molecule itself. That distinction should shape which platform you choose, not just the price.
How do the three compare on the things that matter?
| Factor | Ro | Henry Meds | Hims |
|---|---|---|---|
| Typical medication route | Branded, insurance help | Compounded, flat cash | Mixed, shifts over time |
| Pricing model | Copay or self-pay | Low monthly flat fee | Monthly flat or branded price |
| Clinician contact | Structured, messaging based | Lighter touch | Broad consumer platform |
| Best fit | People with some coverage | Cash payers wanting low price | Brand-familiar buyers |
What does each one actually cost?
Cash prices move often, so treat any figure you see as this month’s number, not a fixed rate. Compounded programs like Henry Meds have historically posted the lowest flat monthly totals, sometimes a few hundred dollars, because there is no insurance in the loop and no branded list price to discount from. Branded access through Ro tends to land near manufacturer self-pay figures, which are higher but buy an FDA-approved product.
Hims sits in the middle and has changed its offering more than once, so the sustainable monthly price matters more than the introductory one. Anyone comparing these against other supervised telehealth options, including flat-price compounded programs described at formblends.com, should read what the fee includes before comparing stickers, since some prices bundle the medication and some do not.
One honest note: the cheapest option is not automatically the best value. A low compounded price that comes with thin clinical review is a worse deal than a higher one with a clinician who checks your history, and the reverse can be true too. Price alone is a weak tiebreaker.
How much does the medication choice itself matter?
A lot, and the evidence is uneven across the two molecules. Tirzepatide has produced larger average weight reduction in its trials than semaglutide has in its own, and the 2024 direct comparison favored tirzepatide on weight outcomes. Both belong to a drug class also used in type 2 diabetes, as summarized in a 2019 review of diabetes therapies, which is why prescribing history and other conditions belong in the decision.
If a platform only offers one molecule, that constraint may matter more than any pricing difference between the three companies. A prescriber who can consider both, and who documents your case, is worth more than a marginally lower monthly fee.
What separates a safe program from a risky one?
The FDA’s guidance on compounding explains that compounded drugs fill gaps for specific patients but do not carry the same premarket assurance as approved products. A 2025 clinician-facing review on navigating compounded semaglutide reaches a similar practical point: oversight, clear dosing, and provider involvement are what reduce harm. The platforms that do this well share a real clinical review, plain labeling, and dosing that comes from a clinician rather than a chart the patient interprets alone. The ones that cut those corners are the ones tied to the reported administration errors.
Key takeaways
- No platform wins outright; the branded-versus-compounded choice decides more than the brand name.
- Compounded medication is not FDA-approved and carries documented dosing and handling risks.
- Henry Meds usually posts the lowest compounded cash price; Ro leans branded and coverage-aware.
- Clinical oversight and which molecule is offered matter more than a small price gap.
See also: Personal Accident Lawyer: Important Steps to Take After an Unexpected Injury
Frequently asked questions
Which platform is cheapest for GLP-1 care?
It depends on whether you want branded or compounded medication. Compounded programs usually post lower flat monthly prices, while branded access through any platform lands near manufacturer self-pay figures. The cheapest sticker is not always the better value once safety and supply are weighed.
Do Ro, Henry Meds, and Hims prescribe the same drugs?
Not exactly. All three connect patients with licensed clinicians who may prescribe semaglutide or tirzepatide, but the specific offering shifts with supply, state rules, and whether the platform is routing to branded product or a compounding pharmacy.
Is compounded medication from these platforms FDA-approved?
No. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They have not been through the approval process behind the branded trial evidence.
Does insurance work with these platforms?
Often not for the medication itself. Many telehealth GLP-1 programs run on cash pricing because plans frequently exclude weight management drugs, so patients pay a flat monthly fee rather than a copay.
What should be checked before picking a platform?
Whether you are getting branded or compounded medication, what the price includes, and whether a real licensed clinician reviews your case. Those three answers matter more than the brand name on the app.
